(Q37809538)

23 August 2017

title

Pharmacokinetic evaluation of continuous intravenous epoprostenol (English)

1 reference

23 August 2017

1 reference

3

0 references

David Montani

8

0 references

Marie-Camille Chaumais

object named as

Marie-Camille Chaumais

1

0 references

Olivier Sitbon

object named as

Olivier Sitbon

6

0 references

Marc Humbert

object named as

Marc Humbert

5

0 references

author name string

Marion Jobard

2

1 reference

23 August 2017

Claire Vignand-Courtin

4

1 reference

23 August 2017

André Rieutord

7

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

23 August 2017

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1587-1598

1 reference

Prostanoids and prostanoid receptors in signal transduction

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prostacyclin: A Vascular Mediator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Regulatory functions of the vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

The chemical structure of prostaglandin X (prostacyclin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Pharmacodynamic profile of prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prostacyclin therapies for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Cardioprotective prostacyclin signaling in vascular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Physiologic basis for the treatment of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Studies on the protective effect of prostacyclin in acute myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Concurrent down-regulation of IP prostanoid receptors and the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs) during prolonged exposure of neuroblastoma x glioma cells to prostanoid agonists. Quantification and functional im

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Myosin light chain phosphatase: subunit composition, interactions and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prostacyclin-dependent apoptosis mediated by PPAR delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prostanoid receptors involved in the relaxation of human pulmonary vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Internalization and sequestration of the human prostacyclin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Evidence-based pharmacologic management of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Epoprostenol in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

The new clinical trials on pharmacological treatment in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Guidelines for the diagnosis and treatment of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prostanoid therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Pulmonary veno-occlusive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Bloodstream infections in patients given treatment with intravenous prostanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Prostacyclin in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Severe erythroderma as a complication of continuous epoprostenol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Pulmonary veno-occlusive disease: recent progress and current challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Treatment of pulmonary arterial hypertension in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Pregnancy and primary pulmonary hypertension : successful outcome with epoprostenol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.534458

10.1517/17425255.2010.534458

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference